➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
AstraZeneca
Harvard Business School
McKesson
Mallinckrodt
McKinsey

Last Updated: August 7, 2020

DrugPatentWatch Database Preview

Claims for Patent: 6,524,852

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Patent: 6,524,852
Title: Removing or increasing permeability of embryonic capsule to prepare equine embryos for cryopreservation
Abstract:A method for preparing an equine embryo for cryopreservation is provided. The method includes collecting an equine embryo with its embryonic capsule. Then after collection the embryo is treated to eliminate or increase the permeability of the capsule in which to enhance subsequent action of cryoprotectant(s). After the treatment the embryo is contacted with cryoprotectant(s) and then placed in a straw with the cryoprotectant(s). Furthermore, the capsule can be treated with enzymes such as collagenase and/or trypsin. Also the embryonic capsule may be removed by mechanical means before subjecting it to the action of cryoprotectant(s). The embryo may also be subjected to an enzymatic treatment to weaken the capsule.
Inventor(s): Legrand; Emmanuel (61200 Sevigny, FR)
Assignee: Legrand; Emmanuel (Sevigny, FR) Legrand; Rene (Sevigny, FR) Legrand; Odile (Sevigny, FR) Legrand; Richard (Sevigny, FR) Legrand; Jean-Pierre (Sevigny, FR) Buisson; Corinne Legrand (Bailleul, FR)
Application Number:09/445,740
Patent Claims:1. Method for preparing an equine embryo for cryopreservation, said method comprising collecting an equine embryo having an embryonic capsule, subjecting the collected embryo to treatment to eliminate the embryonic capsule, or to increase permeability of the embryonic capsule to enhance subsequent action of cryoprotectant(s), contacting the treated embryo with cryoprotectant(s), and placing the treated embryo and cryoprotectant(s) in a straw to obtain said equine embryo for cryopreservation.

2. Method according to claim 1, wherein said treatment to eliminate, or increase permeability of the embryonic capsule is by enzymatic action.

3. Method according to claim 2, wherein said treatment is by immersing the embryo in a bath of collagenase.

4. Method according to claim 3, wherein said treatment is with 2.5% collagenase for 15 min at ambient temperature.

5. Method according to claim 2, wherein said treatment is by immersing the embryo in a bath of trypsin.

6. Method according to claim 5, wherein said treatment is with 0.2% trypsin for 15 min at ambient temperature.

7. Method according to claim 2, wherein said treatment is with a mixture of collagenase and trypsin.

8. Method according to claim 1, wherein said treatment to eliminate, or increase permeability of the embryonic capsule is performed mechanically.

9. Method according to claim 8, wherein before said treatment said embryo is subjected a to chemical treatment to weaken said capsule.

10. Method according to claim 9, wherein before said treatment, said embryo is subjected to an enzymatic treatment to weaken the capsule.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
France97 07311Jun 10, 1997
PCT Information
PCT FiledJune 10, 1998PCT Application Number:PCT/FR98/01190
PCT Publication Date:December 17, 1998PCT Publication Number:WO98/56246

Details for Patent 6,524,852

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Smith And Nephew SANTYL collagenase OINTMENT;TOPICAL 101995 001 1965-06-04   Start Trial Legrand; Emmanuel (Sevigny, FR) Legrand; Rene (Sevigny, FR) Legrand; Odile (Sevigny, FR) Legrand; Richard (Sevigny, FR) Legrand; Jean-Pierre (Sevigny, FR) Buisson; Corinne Legrand (Bailleul, FR) 2017-06-10 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
McKesson
Johnson and Johnson
Mallinckrodt
Moodys
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.